Results 201 to 210 of about 502,764 (268)

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Challenges and progress in RNA velocity: Comparative analysis across multiple biological contexts. [PDF]

PLoS Comput Biol
Ancheta S, Dorman L, Le Treut G, Gurung A, Huber G, Royer LA, Granados A, Lange M.   +7 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

Molecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours   +11 more
wiley   +1 more source

A DNA Methylation–based Computational Framework for Tumour–microenvironment State Inference and Molecular Stratification

Hamese S, Takundwa M, Prinsloo E, Govindaraj DBT.   +3 more
europepmc   +1 more source

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET). [PDF]

Lancet Reg Health Am
Reeves BN, El Chaer F, Foltz L, Tashi T, Abu-Zeinah G, Qin A, Lucas J, Halpern AB, Maze D, Safah H, O'Connell CL, Goel S, Rein L, Fang B, How J, Babu S, Li Z, Cerquozzi S, Oh ST, Hunter AM, Podoltsev N, Vachhani P, Cunningham JM, Hillis C, Bose P, Yacoub A, Mascarenhas J, Zagrijtschuk O, Castro H, Mesa RA, Masarova L.   +30 more
europepmc   +1 more source

A fuzzy logic model for taxi service assessment using passenger survey data from Ukraine and Poland. [PDF]

Sci Rep
Medvediev I, Kyrii Y, Smyrnova O, Muzylyov D.   +3 more
europepmc   +1 more source

Precision Medicine Gene Network Analyser: part I-cancer driver gene identification through network topology and ensemble machine learning. [PDF]

Genomics Inform
Siddalingappa R, Hussain S, S D, Dheerendra P, Gornale S, B L M, Kothandan G.   +6 more
europepmc   +1 more source

Clonal biases dictate availability of colonic cancer driver mutations for transformation. [PDF]

Nat Commun
Skoufou-Papoutsaki N, Kemp R, Adler S, Marks K, Girard AC, Mehmed S, Lourenço FC, Moutin EB, Ten Hoopen R, Morrissey E, Winton DJ, Tourigny DS.   +11 more
europepmc   +1 more source